Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Weighted Average) (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 22.25% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 22.25%, while the annual FY2024 figure was $1.2 million, 10.99% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $1.5 million in Q3 2025 per NWBO's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $1.5 million in Q3 2025 and bottomed at $834605.0 in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $1.1 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 30.33% in 2021, then increased 7.59% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $873517.0 in 2021, then rose by 16.29% to $1.0 million in 2022, then rose by 10.17% to $1.1 million in 2023, then grew by 10.99% to $1.2 million in 2024, then rose by 20.11% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $1.5 million in Q3 2025, $1.4 million in Q2 2025, and $1.4 million in Q1 2025.